bevacizumab
| Product Overview | |
| Generic Name | bevacizumab |
| Brand Name(s) | Avastin® |
| Form | Solution for intravenous infusion; single-dose vial |
| Strength | 100 mg/4 mL (25 mg/mL); 400 mg/16 mL (25 mg/mL) |
| Therapeutic Class | Antineoplastic agent; recombinant humanized monoclonal antibody / VEGF inhibitor |
| ATC Code | L01FG01 |
| Manufacturing & Regulatory | |
| GMP Compliance | WHO-GMP, EU-GMP |
| COFEPRIS | Under Registration (2025) |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 24 Months |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
